404 related articles for article (PubMed ID: 20685942)
1. Mitochondrial SIRT3 and heart disease.
Pillai VB; Sundaresan NR; Jeevanandam V; Gupta MP
Cardiovasc Res; 2010 Nov; 88(2):250-6. PubMed ID: 20685942
[TBL] [Abstract][Full Text] [Related]
2. Emerging characterization of the role of SIRT3-mediated mitochondrial protein deacetylation in the heart.
Sack MN
Am J Physiol Heart Circ Physiol; 2011 Dec; 301(6):H2191-7. PubMed ID: 21984547
[TBL] [Abstract][Full Text] [Related]
3. Sirt3 protects mitochondrial DNA damage and blocks the development of doxorubicin-induced cardiomyopathy in mice.
Pillai VB; Bindu S; Sharp W; Fang YH; Kim G; Gupta M; Samant S; Gupta MP
Am J Physiol Heart Circ Physiol; 2016 Apr; 310(8):H962-72. PubMed ID: 26873966
[TBL] [Abstract][Full Text] [Related]
4. Emerging beneficial roles of sirtuins in heart failure.
Tanno M; Kuno A; Horio Y; Miura T
Basic Res Cardiol; 2012 Jul; 107(4):273. PubMed ID: 22622703
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-195 Regulates Metabolism in Failing Myocardium Via Alterations in Sirtuin 3 Expression and Mitochondrial Protein Acetylation.
Zhang X; Ji R; Liao X; Castillero E; Kennel PJ; Brunjes DL; Franz M; Möbius-Winkler S; Drosatos K; George I; Chen EI; Colombo PC; Schulze PC
Circulation; 2018 May; 137(19):2052-2067. PubMed ID: 29330215
[TBL] [Abstract][Full Text] [Related]
6. Sirtuin 3 Deficiency Accelerates Hypertensive Cardiac Remodeling by Impairing Angiogenesis.
Wei T; Huang G; Gao J; Huang C; Sun M; Wu J; Bu J; Shen W
J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862956
[TBL] [Abstract][Full Text] [Related]
7. SIRT3 as a potential therapeutic target for heart failure.
Chen J; Chen S; Zhang B; Liu J
Pharmacol Res; 2021 Mar; 165():105432. PubMed ID: 33508434
[TBL] [Abstract][Full Text] [Related]
8. Glutaredoxin-2 and Sirtuin-3 deficiencies impair cardiac mitochondrial energetics but their effects are not additive.
Boardman NT; Migally B; Pileggi C; Parmar GS; Xuan JY; Menzies K; Harper ME
Biochim Biophys Acta Mol Basis Dis; 2021 Jan; 1867(1):165982. PubMed ID: 33002579
[TBL] [Abstract][Full Text] [Related]
9. Regulation of the mPTP by SIRT3-mediated deacetylation of CypD at lysine 166 suppresses age-related cardiac hypertrophy.
Hafner AV; Dai J; Gomes AP; Xiao CY; Palmeira CM; Rosenzweig A; Sinclair DA
Aging (Albany NY); 2010 Dec; 2(12):914-23. PubMed ID: 21212461
[TBL] [Abstract][Full Text] [Related]
10. Receptor-interacting Protein 140 represses Sirtuin 3 to facilitate hypertrophy, mitochondrial dysfunction and energy metabolic dysfunction in cardiomyocytes.
You J; Yue Z; Chen S; Chen Y; Lu X; Zhang X; Shen P; Li J; Han Q; Li Z; Liu P
Acta Physiol (Oxf); 2017 May; 220(1):58-71. PubMed ID: 27614093
[TBL] [Abstract][Full Text] [Related]
11. Sirtuin-3 (SIRT3) Protein Attenuates Doxorubicin-induced Oxidative Stress and Improves Mitochondrial Respiration in H9c2 Cardiomyocytes.
Cheung KG; Cole LK; Xiang B; Chen K; Ma X; Myal Y; Hatch GM; Tong Q; Dolinsky VW
J Biol Chem; 2015 Apr; 290(17):10981-93. PubMed ID: 25759382
[TBL] [Abstract][Full Text] [Related]
12. The modulation of SIRT1 and SIRT3 by natural compounds as a therapeutic target in doxorubicin-induced cardiotoxicity: A review.
Tabrizi FB; Yarmohammadi F; Hayes AW; Karimi G
J Biochem Mol Toxicol; 2022 Jan; 36(1):e22946. PubMed ID: 34747550
[TBL] [Abstract][Full Text] [Related]
13. Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial Sirt3.
Pillai VB; Samant S; Sundaresan NR; Raghuraman H; Kim G; Bonner MY; Arbiser JL; Walker DI; Jones DP; Gius D; Gupta MP
Nat Commun; 2015 Apr; 6():6656. PubMed ID: 25871545
[TBL] [Abstract][Full Text] [Related]
14. The role of sirtuins in cardiac disease.
Matsushima S; Sadoshima J
Am J Physiol Heart Circ Physiol; 2015 Nov; 309(9):H1375-89. PubMed ID: 26232232
[TBL] [Abstract][Full Text] [Related]
15. SIRT3: A New Regulator of Cardiovascular Diseases.
Sun W; Liu C; Chen Q; Liu N; Yan Y; Liu B
Oxid Med Cell Longev; 2018; 2018():7293861. PubMed ID: 29643974
[TBL] [Abstract][Full Text] [Related]
16. Hydrogen sulfide pretreatment improves mitochondrial function in myocardial hypertrophy via a SIRT3-dependent manner.
Meng G; Liu J; Liu S; Song Q; Liu L; Xie L; Han Y; Ji Y
Br J Pharmacol; 2018 Apr; 175(8):1126-1145. PubMed ID: 28503736
[TBL] [Abstract][Full Text] [Related]
17. 2-APQC, a small-molecule activator of Sirtuin-3 (SIRT3), alleviates myocardial hypertrophy and fibrosis by regulating mitochondrial homeostasis.
Peng F; Liao M; Jin W; Liu W; Li Z; Fan Z; Zou L; Chen S; Zhu L; Zhao Q; Zhan G; Ouyang L; Peng C; Han B; Zhang J; Fu L
Signal Transduct Target Ther; 2024 May; 9(1):133. PubMed ID: 38744811
[TBL] [Abstract][Full Text] [Related]
18. Exogenous H
Sun Y; Tian Z; Liu N; Zhang L; Gao Z; Sun X; Yu M; Wu J; Yang F; Zhao Y; Ren H; Chen H; Zhao D; Wang Y; Dong S; Xu C; Lu F; Zhang W
J Mol Med (Berl); 2018 Apr; 96(3-4):281-299. PubMed ID: 29349500
[TBL] [Abstract][Full Text] [Related]
19. The role of SIRT3 in mitochondrial homeostasis and cardiac adaptation to hypertrophy and aging.
Sack MN
J Mol Cell Cardiol; 2012 Mar; 52(3):520-5. PubMed ID: 22119802
[TBL] [Abstract][Full Text] [Related]
20. Sirt3 is a novel target to treat sepsis induced myocardial dysfunction by acetylated modulation of critical enzymes within cardiac tricarboxylic acid cycle.
Xu Y; Zhang S; Rong J; Lin Y; Du L; Wang Y; Zhang Z
Pharmacol Res; 2020 Sep; 159():104887. PubMed ID: 32526680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
